Subgroup analysesSubgroup analyses by dose of BHT suggested that higher doses of BHT may be associated with more effectiveness but also higher risk of adverse effects .
There was low to moderate quality evidence that BHT in various forms and doses is more effective than placebo for treating moderate to severe menopausal hot flushes .
There was some evidence to suggest that higher doses of BHT are associated with greater effectiveness but also with higher risk of adverse effects .
No data are yet available about the safety of BHT with regard to long-term outcomes such as heart attack , stroke and breast cancer .
BACKGROUND Various hormone therapies ( HT ) are available to treat  menopausal vasomotor symptoms .
Bioidentical hormones are chemically identical to those produced by the human body , and several types are well-tested and available on prescription .
Many women have opted for bioidentical hormone therapy ( BHT ) on the assumption that it is safer than other forms of HT .
We evaluated the evidence .
OBJECTIVES To determine the effectiveness and safety of bioidentical hormones compared to placebo or non-bioidentical hormones for the relief of vasomotor symptoms .
Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women.
OBJECTIVES We sought to compare the effects of estrogen/transvaginal progesterone gel with estrogen/medroxyprogesterone acetate ( MPA ) on exercise-induced myocardial ischemia in postmenopausal women with coronary artery disease or previous myocardial infa rct ion , or both . BACKGROUND Estrogen therapy beneficially affects exercise-induced myocardial ischemia in postmenopausal women ; however , women with an intact uterus also take progestin to protect against uterine malignancies . The effects of combination estrogen/progestin therapy on myocardial ischemia are unknown . METHODS Eighteen postmenopausal women ( mean + /- SD age 59+/-7 years ) were given 17-beta-estradiol in single-blinded manner for four weeks ( 1 mg/day for three weeks then 2 mg/day for one week ) . Estradiol ( 2 mg/day ) was then continued , and the patients were r and omized ( double-blind ) for 12 days to either transvaginal progesterone gel ( 90 mg on alternate days ) and oral MPA placebo ( 10 mg/day ) , or vice versa . After another two weeks on estradiol alone , the patients crossed over to progestin treatment and repeated the protocol on the opposite treatment . Patients underwent treadmill exercise testing after each estradiol phase and at day 10 of each progestin phase . RESULTS Exercise time to myocardial ischemia increased after the first estrogen phase as compared with baseline ( mean difference with 95 % confidence interval [ CI ] : 72 s [ 34 to 110 ] , p = 0.001 ) , and was increased by combination estradiol/progesterone therapy as compared with estradiol/MPA therapy ( 92 s [ 35 to 149 ] , p = 0.001 ) ) . Two patients ( 11 % ) were withdrawn while taking estradiol/MPA owing to unstable angina . CONCLUSIONS Combination estrogen/transvaginal progesterone gel increases exercise time to myocardial ischemia , as compared with estrogen/MPA . These results imply that the choice of progestin in women at higher cardiovascular risk requires careful consideration
Subgroup analysesSubgroup analyses by dose of BHT suggested that higher doses of BHT may be associated with more effectiveness but also higher risk of adverse effects .
There was low to moderate quality evidence that BHT in various forms and doses is more effective than placebo for treating moderate to severe menopausal hot flushes .
There was some evidence to suggest that higher doses of BHT are associated with greater effectiveness but also with higher risk of adverse effects .
No data are yet available about the safety of BHT with regard to long-term outcomes such as heart attack , stroke and breast cancer .
BACKGROUND Various hormone therapies ( HT ) are available to treat  menopausal vasomotor symptoms .
Bioidentical hormones are chemically identical to those produced by the human body , and several types are well-tested and available on prescription .
Many women have opted for bioidentical hormone therapy ( BHT ) on the assumption that it is safer than other forms of HT .
We evaluated the evidence .
OBJECTIVES To determine the effectiveness and safety of bioidentical hormones compared to placebo or non-bioidentical hormones for the relief of vasomotor symptoms .